

## References

### Antimicrobial Resistance Programs in Canada

1. Antimicrobial resistance programs in Canada 1995-2010: a critical evaluation. Conly JM. *Antimicrob Resist Infect Control*. 2012;1:10.
2. Declines in outpatient antimicrobial use in Canada (1995-2010). Finley R, Glass-Kaasta SK, Hutchinson J, Patrick DM, Weiss K, Conly. *PLOS One* 2013;8:e76398.
3. Obstacles to developing a multinational report card on antimicrobial resistance for Canada: an evidence-based review. Stephen C, Parmley J, Dawson-Coates J, Fraser E, Conly J. *Microb Drug Resist*. 2007;13:251-60
4. Surveillance for antimicrobial resistant organisms: potential sources and magnitude of bias. Rempel OR, Laupland KB. *Epidemiol Infect*. 2009;137:1665-73.

### Antibiotic Resistance in Gram-positive Organisms

#### VRE

5. Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999-2005. Ofner-Agostini M, Johnston BL, Simor AE, Embil J, Matlow A, Mulvey M, Ormiston D, Conly J; Canadian Nosocomial Infection Surveillance Program. *Infect Control Hosp Epidemiol*. 2008 Mar;29(3):271-4. doi: 10.1086/528812.

#### MRSA/VISA/VRSA

6. Changing epidemiology of methicillin-resistant *Staphylococcus aureus* in Canada. Nichol KA, Adam HJ, Roscoe DL, Golding GR, Lagacé-Wiens PR, Hoban DJ, Zhanel GG; Canadian Antimicrobial Resistance Alliance. *J Antimicrob Chemother*. 2013 May;68 Suppl 1:i47-55.
7. Methicillin-resistant *Staphylococcus aureus* colonization or infection in Canada: National Surveillance and Changing Epidemiology, 1995-2007. Simor AE, Gilbert NL, Gravel D, Mulvey MR, Bryce E, Loeb M, Matlow A, McGeer A, Louie L, Campbell J; Canadian Nosocomial Infection Surveillance Program. *Infect Control Hosp Epidemiol*. 2010 Apr;31(4):348-56.
8. National surveillance of methicillin-resistant *Staphylococcus aureus* among hospitalized pediatric patients in Canadian acute care facilities, 1995-2007. Matlow A, Forgie S, Pelude L, Embree J, Gravel D, Langley JM et al. *Pediatr Infect Dis J*. 2012;31:814-20
9. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Marra F, Patrick DM, Chong M, McKay R, Hoang L, Bowie WR. *Antimicrob Agents Chemother*. 2012;56:6243-49

### Antibiotic Resistance in Gram-negative Organisms

#### *Neisseria gonorrhoeae*

10. *Neisseria gonorrhoeae* treatment failure and susceptibility to cefixime in Toronto, Canada. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, Siebert H, Towns L, Melano RG, Low DE. *JAMA*. 2013 Jan 9;309(2):163-70. doi: 10.1001/jama.2012.176575.
11. Molecular analysis of antimicrobial resistance mechanisms in *Neisseria gonorrhoeae* isolates from Ontario, Canada. Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, Perusini SJ, Towns L, Lo S, Low DE, Melano RG. *Antimicrob Agents Chemother*. 2011 Feb;55(2):703-12. doi: 10.1128/AAC.00788-10. Epub 2010 Nov 22.
12. Emergence and characterization of *Neisseria gonorrhoeae* isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada, 2001-2010. Martin I, Sawatzky P, Allen V, Hoang L, Lefebvre B, Mina N et al. *Sex*

Enterobacteriaceae

13. Molecular Epidemiology over an 11-Year Period (2000 to 2010) of Extended-Spectrum  $\beta$ -Lactamase-Producing *Escherichia coli* Causing Bacteremia in a Centralized Canadian Region. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum beta-lactamase-producing *Escherichia coli* causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50:294-99 doi: 10.1128/JCM.06025-11
14. Decreased Susceptibility to Noncarbapenem Antimicrobials in Extended-Spectrum- $\beta$ -Lactamase-Producing *Escherichia coli* and *Klebsiella pneumoniae* Isolates in Toronto, Canada. Christopher F. Lowe, Allison McGeer, Matthew P. Muller, Kevin Katz. Antimicrob Agents Chemother. 2012 July; 56(7): 3977–3980. doi: 10.1128/AAC.00260-12
15. Characterization of methicillin-resistant *Staphylococcus aureus*, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing *Escherichia coli* in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) study (2005–2006). George G Zhanel, Mel DeCorby, Kim A Nichol, Patricia J Baudry, James A Karlowsky, Philippe RS Lagace-Wiens, Melissa McCracken, Michael R Mulvey, Daryl J Hoban. Can J Infect Dis Med Microbiol. 2008 May; 19(3): 243–249.
16. Ambler Class A Extended-Spectrum Beta-Lactamase-Producing *Escherichia coli* and *Klebsiella* spp. in Canadian Hospitals. Michael R. Mulvey, Elizabeth Bryce, David Boyd, Marianna Ofner-Agostini, Sara Christianson, Andrew E. Simor, Shirley Paton, The Canadian Hospital Epidemiology Committee of The Canadian Nosocomial Infection Surveillance Program, Health Canada. Antimicrob Agents Chemother. 2004 April; 48(4): 1204–1214. doi: 10.1128/AAC.48.4.1204-1214.2004
17. Molecular epidemiology of extended-spectrum beta-lactamase-, AmpC beta-lactamase- and carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. Denisuk AJ, Lagace-Wiens PR, Pitout JD, Mulvey MR, Simner PJ, Taylor F et al. J Antimicrob Chemother. 2013;68 (Suppl 1):i57-i65.
18. New Delhi metallo- $\beta$ -lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. Julianne V. Kus, Manal Tadros, Andrew Simor, Donald E. Low, Allison J. McGeer, Barbara M. Willey, Cindy Larocque, Karen Pike, Iris-Ann Edwards, Helen Dedier, Roberto Melano, David A. Boyd, Michael R. Mulvey, Lisa Louie, Christopher Okeahialam, Mark Bayley, Cynthia Whitehead, Denyse Richardson, Lesley Carr, Fatema Jinnah, Susan M. Poutanen. CMAJ. 2011 August 9; 183(11): 1257–1261
19. Characterization of *Acinetobacter baumannii* and meropenem-resistant *Pseudomonas aeruginosa* in Canada: results of the CANWARD 2007-2009 study. McCracken M, Mataseje LF, Loo V, Walkty A, Adam HJ, Hoban DJ et al. Diagn Microbiol Infect Dis. 2011;69:335-41

**Drug-resistant *Mycobacterium tuberculosis* and *Candida* spp.**

MDR /XDR TB

20. Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics. Minion J, Gallant V, Wolfe J, Jamieson F, Long R. PLoS One. 2013;8(1):e53466.

Candida species

21. Epidemiology and antifungal susceptibility of bloodstream *Candida* isolates in Quebec: Report on 453 cases between 2003 and 2005.
22. Epidemiology and antifungal susceptibility of bloodstream *Candida* isolates in Quebec: Report on 453 cases between 2003 and 2005. St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, Libman M. Can J Infect Dis Med Microbiol. 2008 Jan;19(1):55-62.

23. Susceptibility patterns of *Candida* species recovered from Canadian intensive care units Laverdiere M, Labbé AC, Restieri C, Rotstein C, Heyland D, Madger S, Stewart T. *J Crit Care*. 2007 Sep;22(3):245-50. Epub 2007 Jan 31.
24. A single-centre 10-year experience with *Candida* bloodstream infections. Labbe AC, Pepin J, Patino C, Castonguay S, Restieri C, Laverdiere M. *Can J Infect Dis Med Microbiol*. 2009;20:45-50

### **Healthcare-Associated and Community-acquired Pathogens**

25. Antimicrobial resistance trends in the Province of British Columbia, 2012. BCCDC, Do Bugs Need Drugs? Program, Provincial Health Service Authority. BC, August 2013
- 26 Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11. Lagace-Wiens PR, Adam HJ, Low DE, Blondeau JM, Baxter MR, Denisuik AJ et al. *J Antimicrob Chemother*. 2013;68 Suppl 1:i23-i29
- 27 Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ et al. *J Antimicrob Chemother*. 2013;68 Suppl 1:i17-22.